Zacks Investment Research upgraded shares of GW PHARMA-ADR (GWPH) from NEUTRAL to OUTPERFORM on October 02, 2014, with a target price of $96.40.
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on GW PHARMA-ADR (GWPH),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment